CDRH More Reliant On SEC, FTC For Ad/Promotion Vigilance Under Policy Shift
This article was originally published in The Gray Sheet
Executive Summary
The Center for Devices & Radiological Health increasingly is looking to other federal agencies to help regulate medical device advertising and promotion as it scales back its own claim enforcement activities
You may also be interested in...
FDA Centralizes Internal Procedure For SEC Communications
FDA's new process for referring information to the Securities & Exchange Commission could result in heightened CDRH attention to potentially false or misleading statements by device firms
FDA Centralizes Internal Procedure For SEC Communications
FDA's new process for referring information to the Securities & Exchange Commission could result in heightened CDRH attention to potentially false or misleading statements by device firms
FDA Will Not Be “Health SEC,” Chief Counsel Troy Tells Investors
FDA and the Securities & Exchange Commission are making progress on formalizing communications about potentially misleading disclosures to investors, FDA Chief Counsel Dan Troy told attendees of a Schwab Washington Research Group conference May 15